dibutyl cis-cyclohexane-1,4-dicarboxylate | 126770-66-9

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: dibutyl cis-cyclohexane-1,4-dicarboxylate
• CAS: 126770-66-9
• 化学式: C₁₆H₂₈O₄
• 分子量: 284.396
• InChiKey: QGUFKMSGOYILME-OKILXGFUSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.48
• 重原子数：
  20.0
• 可旋转键数：
  8.0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  52.6
• 氢给体数：
  0.0
• 氢受体数：
  4.0

反应信息

• 作为产物：
  描述：

  cis-4-(butoxycarbonyl)cyclohexanecarboxylic acid 在 硼烷 作用下， 以 四氢呋喃 为溶剂， 反应 3.33h， 以75%的产率得到butyl cis-4-(hydroxymethyl)cyclohexanecarboxylate
  参考文献：
  名称：

  4-Cycloalkylaminopyrazolo pyrimidine NMDA/NR2B antagonists

  摘要：

  由公式(I)表示的化合物或其药用可接受的盐，作为NMDA/NR2B拮抗剂具有疗效，可用于治疗神经病症，例如疼痛、帕金森病、阿尔茨海默病、癫痫、抑郁症、焦虑症、缺血性脑损伤包括中风以及其他疾病。

  公开号：

  US20050054658A1

文献信息

• 1-Alkyl-1-azoniabicyclo' 2.2.!octane carbamate derivatives and their use as muscarinic receptor antagonists
  申请人：Catena Ruiz Lorenzo Juan

  公开号：US20050043349A1

  公开（公告）日：2005-02-24

  Carbamate of general formula (I), wherein R1, R2, and R3 are H, OH, NO 2 , SH, CN, F, Cl, Br, I, COOH, CONH 2 , (C 1 -C 4 )-alkoxycarbonyl, (C 1 -C 4 )-alkylsulfanyl, (C 1 -C 4 )-alkylsulfinyl, (C 1 -C 4 )-alkylsulfonyl, (C 1 -C 4 )-alkoxyl optionally substituted with one or several F, and (C 1 -C 4 )-alkyl optionally substituted with one or several F or OH; R4 is cycloalkyl, phenyl, heteroaryl or a bicyclic ring system; R5 is cycloalkyl, (C 5 -C 10 )-alkyl, a substituted (C 1 -C 10 )-alkyl; and X − is a physiologically acceptable anion. Carbamate (I) is selective M 3 receptor antagonists versus M 2 receptor and may be used for the treatment of urinary incontinence (particularly, the one caused by overactive bladder), irritable bowel syndrome, and respiratory disorders (particularly, chronic obstructive pulmonary disease, chronic bronchitis, asthma, emphysema, and rhinitis), as well as in ophthalmic interventions.

  通式（I）的氨基甲酸酯，其中R1，R2和R3为H，OH，NO2，SH，CN，F，Cl，Br，I，COOH，CONH2，（C1-C4）-烷氧基羰基，（C1-C4）-烷基硫基，（C1-C4）-烷基亚砜基，（C1-C4）-烷基磺酰基，（C1-C4）-烷氧基可选地取代一个或多个F，以及（C1-C4）-烷基可选地取代一个或多个F或OH; R4是环烷基，苯基，杂环芳基或双环环系统; R5是环烷基，（C5-C10）-烷基，取代的（C1-C10）-烷基; X-是生理上可接受的阴离子。氨基甲酸酯（I）是选择性M3受体拮抗剂，对M2受体具有较高的选择性，可用于治疗尿失禁（尤其是由过度活跃的膀胱引起的），肠易激综合征和呼吸系统疾病（尤其是慢性阻塞性肺疾病，慢性支气管炎，哮喘，肺气肿和鼻炎），以及眼科干预。
• Cellulose Compound Film, Optical Compensation Sheet, Polarizing Plate, and Liquid Crystal Display Device
  申请人：Nozoe Yutaka

  公开号：US20070259134A1

  公开（公告）日：2007-11-08

  A cellulose compound film containing a cellulose compound having two or more substituents whose polarizability anisotropies Δα calculated by mathematical formula (1) are different from each other, wherein substitution degrees of the following substituents A and B in the cellulose compound satisfy relationship as defined by mathematical formula (A1), in which the substituent A has the lowest Δα and the substituent B has the highest Δα: Δ ⁢ ⁢ α = α ⁢ ⁢ x - α ⁢ ⁢ y + α ⁢ ⁢ z 2 Mathematical ⁢ ⁢ formula ⁢ ⁢ ( 1 ) wherein, in characteristic values obtained after diagonalization of polarizability tensor, αx is the largest component, αy is the second largest component, and αz is the smallest component; DS B 2+ DS B 3− DS B 6≧−0.1   Mathematical formula (A1) wherein DS B 2, DS B 3, and DS B 6 represent a substitution degree of the substituent B at the 2-, 3-, or 6-position of a β-glucose ring constituting unit of cellulose, respectively; and an optical compensation film, a polarizing plate, and a liquid crystal display device, using the cellulose compound film.

  一种纤维素化合物薄膜，其含有具有两个或更多取代基的纤维素化合物，其极化率各向异性Δα通过数学公式（1）计算得出，其中以下取代基A和B的取代度满足数学公式（A1）所定义的关系，其中取代基A具有最低的Δα，而取代基B具有最高的Δα：Δα = αx-αy + αz2数学公式（1）其中，在极化率张量对角化后获得的特征值中，αx是最大分量，αy是第二大分量，αz是最小分量;DSB2 + DSB3-DSB6≥-0.1数学公式（A1）其中DSB2、DSB3和DSB6分别表示取代基B在纤维素构成单位β-葡萄糖环的2-、3-或6-位置的取代度;以及使用该纤维素化合物薄膜的光学补偿膜、偏光板和液晶显示装置。
• 4-Cycloakylaminopyrazolo pyrimidine nmda/nr2b antagonists
  申请人：Thompson Wayne

  公开号：US20070037829A1

  公开（公告）日：2007-02-15

  Compounds represented by Formula (I) or pharmaceutically acceptable salts thereof, are effective as NMDA/NR2B antagonists useful for treating neurological conditions such as, for example, pain, Parkinson's disease, Alzheimer's disease, epilepsy, depression, anxiety, ischemic brain injury including stroke, and other conditions.

  由公式（I）表示的化合物或其药学上可接受的盐，作为NMDA / NR2B拮抗剂具有疗效，可用于治疗神经系统疾病，例如疼痛，帕金森病，阿尔茨海默病，癫痫，抑郁症，焦虑症，缺血性脑损伤包括中风以及其他疾病。
• Cellulose Acylate Film, Method of Producing the Same, Cellulose Derivative Film, Optically Compensatory Film Using the Same, Optically-Compensatory Film Incorporating Polarizing Plate, Polarizing Plate and Liquid Crystal Display Device
  申请人：Haruta Hiromoto

  公开号：US20090290100A1

  公开（公告）日：2009-11-26

  A method of producing a cellulose derivative film, the method comprising: forming a film with a solvent cast method from a dope including a cellulose derivative satisfying following conditions (a) and (b): (a) at least one among three hydroxyl groups included in a glucose unit of cellulose is substituted by a substituent of which a polarizability anisotropy Δα represented as following Expression (1) is 2.5×10 −24 cm 3 or higher: Expression (1): Δα=αx−(αy+αz)/2, wherein αx, αy and αz is as defined in the specification; and (b) when a substitution degree by a substituent of which Δα is 2.5×10 −24 cm 3 or higher is P A , and a substitution degree by a substituent of which Δα is lower than 2.5×10 −24 cm 3 is P B , the P A and P B satisfy following Expressions (3) and (4): Expression (3): 2P A +P B >3.0; and Expression (4): P A >0.2.

  一种生产纤维素衍生物薄膜的方法，该方法包括：使用包括满足以下条件（a）和（b）的纤维素衍生物的溶胶，通过溶剂浇铸法形成薄膜：（a）纤维素的葡萄糖单元中的三个羟基中的至少一个被取代为极化率各向异性Δα（以下表达式（1）表示）为2.5×10-24cm3或更高的取代基：表达式（1）：Δα=αx-（αy+αz）/ 2，其中αx，αy和αz如规范中定义的；并且（b）当Δα为2.5×10-24cm3或更高的取代基的取代度为PA时，Δα低于2.5×10-24cm3的取代基的取代度为PB，PA和PB满足以下表达式（3）和（4）：表达式（3）：2PA + PB> 3.0；表达式（4）：PA> 0.2。
• 1-ALKYL-1-AZONIABICYCLO (2.2.2) OCTANE CARBAMATE DERIVATIVES AND THEIR USE AS MUSCARINIC RECEPTOR ANTAGONISTS
  申请人：CHIESI FARMACEUTICI S.p.A.

  公开号：EP1461336B1

  公开（公告）日：2013-05-22